Purchase this article with an account.
G. Tosi, W. Schiff, G. Barile, N. Yoshida, S. Chang; Management of Severe Hypotony With Intravitreal Injection of Healon GV . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5493.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To investigate the effect of intravitreal injection of Healon GV® (sodium hyaluronate 1.4%) in the management of severe hypotony. Methods: 0.3 ml of Healon GV was injected intravitreally to treat unresponsive hypotony (1–2 mmHg) following successful repair of longstanding retinal detachment in three patients and following chronic uveitis in one patient. Results: Patients were followed up for 2, 3, 8 and 16 months, respectively. IOP returned within normal range in two patients (14 and 10 mmHg, respectively) and increased from 1 to 5 mmHg in the other two. All patients experienced an improvement in VA, ocular discomfort and ocular findings. No complications were observed. Conclusions: In the four patients here analyzed, intravitreal injection of Healon GV was helpful in reducing the structural and functional changes induced by severe hypotony. A more numerous case series, studied prospectively, is needed before drawing definitive conclusions.
This PDF is available to Subscribers Only